Clinical Trials Browser

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Carcinoma, Ovarian Epithelial, Blast Crisis, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mycosis Fungoides, Myeloproliferative Disorders, Nausea, Neoplasms, Neuroblastoma, Sezary Syndrome, Testicular Neoplasms, Vomiting, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00092183 2017-05-05

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

Phase 4 Completed

866 enrolled

Breast

Breast Neoplasms, Nausea, Vomiting

NCT00092196 2017-05-05

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Phase 3 Completed

820 enrolled

Breast

Breast Neoplasms, Nausea, Vomiting

NCT01432015 2017-03-28

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Phase 4 Completed

20 enrolled 5 charts

Gynecologic

Ovarian Neoplasms, Uterine Neoplasms, Vomiting

NCT02550119 2017-03-28

Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy

Phase NA Terminated

19 enrolled

Gastrointestinal

Gastrointestinal Neoplasms, Nausea, Vomiting

NCT01913990 2017-01-30

ER11-02

Phase 4 Unknown

323 enrolled

Nausea, Vomiting

NCT02576327 2016-12-30

A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation

Phase 4 Unknown

130 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Vomiting, Hematologic Neoplasms

NCT00293384 2016-03-15

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Phase NA Completed

40 enrolled 9 charts

BreastCNSDermatologicGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Testicular Germ Cell Tumor, Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Carcinoma, Ovarian Epithelial, Blast Crisis, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloproliferative Disorders, Nausea, Neuroblastoma, Ovarian Neoplasms, Sezary Syndrome, Testicular Neoplasms, Vomiting, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Gestational Trophoblastic Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02445872 2015-12-09

Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Phase 2 Unknown

80 enrolled

Thoracic

Lung Neoplasms, Nausea, Vomiting

NCT00475085 2015-11-10

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

Phase 3 Completed

1,021 enrolled 10 charts

Breast

Breast Neoplasms, Nausea, Vomiting, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00954941 2015-06-25

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Phase 2 Completed

100 enrolled 7 charts

MyeloidOther hematologic neoplasm

Hematologic Diseases, Myelodysplastic Syndromes, Nausea, Vomiting, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT02407600 2015-04-03

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy

Phase 2 Unknown

150 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Nausea, Vomiting

NCT00314743 2013-05-24

Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation

Phase EARLY_PHASE1 Completed

48 enrolled

Plasma cell

Multiple Myeloma, Nausea, Vomiting

NCT00499668 2013-04-02

Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer

Phase NA Withdrawn

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Pdgfra-Associated Chronic Eosinophilic Leukemia, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Leukemia, Hairy Cell, Leukemia, Mast-Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloproliferative Disorders, Nausea, Polycythemia Vera, Sezary Syndrome, Thrombocythemia, Essential, Vomiting, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, AIDS-Related, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis, Intraocular Lymphoma

NCT00869973 2013-01-23

Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients

Phase 3 Terminated

580 enrolled

Breast

Breast Neoplasms, Vomiting

NCT01012336 2012-10-10

Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin

Phase 2 Completed

89 enrolled 7 charts

Gynecologic

Ovarian Neoplasms, Vomiting

NCT00212602 2012-06-14

ONO-7436 Phase II Study in Japan

Phase 2 Completed

420 enrolled

Nausea, Neoplasms, Vomiting

NCT01046461 2012-02-17

RAD

Phase 2 Unknown

41 enrolled

Nausea, Neoplasms, Vomiting, Postoperative Nausea and Vomiting

NCT00169572 2010-05-10

Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy

Phase 2 Completed

492 enrolled

Nausea, Vomiting

NCT00571168 2010-01-12

EmNa

Phase 3 Unknown

362 enrolled

Plasma cell

Multiple Myeloma, Vomiting

NCT00415103 2009-09-18

AMENO-2

Phase 4 Completed

196 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Nausea, Vomiting

Clinical Trials

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

NRR

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

CINV

The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs

Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients

Efficacy of Aprepitant (Emend®) in Children

Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC

KMEC

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

HDIL2/Emend

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

RAPA

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy

ER11-02

A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy

Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation

Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer

Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients

Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin

ONO-7436 Phase II Study in Japan

RAD

Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy

EmNa

AMENO-2